Opus Genetics (IRD) Net Income (2010 - 2026)
Opus Genetics (IRD) posted quarterly Net Income of -$65.5 million for Q1 2026, down 699.79% year-over-year from $10.9 million in Q1 2025, and down 972.76% quarter-over-quarter from -$6.1 million in Q4 2025.
Analysis
Opus Genetics (IRD) Net Income (2010 - 2026) Analysis & Trends
Opus Genetics (IRD) has reported Net Income for 17 consecutive years, with -$65.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Income fell 699.79% year-over-year to -$65.5 million; the TTM figure through Mar 2026 stood at -$96.5 million (down 64.65% YoY), while the FY2025 annual figure was -$39.2 million, up 31.9% from the prior year.
- Net Income slipped to -$65.5 million in Q1 2026 per IRD's latest filing, from -$6.1 million in the prior quarter.
- Across five years, Net Income topped out at $33.9 million in Q4 2022 and bottomed at -$65.5 million in Q1 2026.
- Historically, Net Income has averaged -$9.1 million across 5 years, with a median of -$6.6 million in 2022.
- Annual changes were most pronounced in 2022 — Net Income surged 637.64% — and 2026, when it plunged 699.79%.
- Opus Genetics' Net Income stood at $33.9 million in 2022, then slumped by 114.13% to -$4.8 million in 2023, then slumped by 632.74% to -$35.1 million in 2024, then jumped by 82.61% to -$6.1 million in 2025, then plunged by 972.76% to -$65.5 million in 2026.
- Business Quant data shows IRD's Net Income at -$65.5 million in Q1 2026, -$6.1 million in Q4 2025, and -$17.5 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Opus Genetics | 446.86 Mn | 358.05 Mn | - | -8.10 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -8.10 Mn |
| Mar 31, 2026 | -65.54 Mn |
| Dec 31, 2025 | -6.11 Mn |
| Sep 30, 2025 | -17.45 Mn |
| Jun 30, 2025 | -7.42 Mn |
| Mar 31, 2025 | -8.19 Mn |
| Dec 31, 2024 | -35.14 Mn |
| Sep 30, 2024 | -7.53 Mn |
| Jun 30, 2024 | -7.77 Mn |
| Mar 31, 2024 | -7.11 Mn |
| Dec 31, 2023 | -4.80 Mn |
| Sep 30, 2023 | 5.56 Mn |
| Jun 30, 2023 | -4.96 Mn |
| Mar 31, 2023 | -5.79 Mn |
| Dec 31, 2022 | 33.94 Mn |
| Sep 30, 2022 | -4.53 Mn |
| Jun 30, 2022 | -4.93 Mn |
| Mar 31, 2022 | -6.60 Mn |
| Dec 31, 2021 | -6.31 Mn |
| Sep 30, 2021 | -4.23 Mn |